MX365365B - Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer. - Google Patents
Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.Info
- Publication number
- MX365365B MX365365B MX2013012346A MX2013012346A MX365365B MX 365365 B MX365365 B MX 365365B MX 2013012346 A MX2013012346 A MX 2013012346A MX 2013012346 A MX2013012346 A MX 2013012346A MX 365365 B MX365365 B MX 365365B
- Authority
- MX
- Mexico
- Prior art keywords
- normal
- tumor cells
- small molecule
- anticancer therapy
- gene induction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen métodos y composiciones que se relacionan a TIC10 de acuerdo a aspectos de la presente invención. Las composiciones y métodos tienen utilidad para tratar enfermedad, particularmente cáncer en un sujeto en necesidad del mismo, incluyendo un sujeto humano así como también sujetos de otras especies. Las composiciones tienen utilidad para tratar cáncer de cerebro en un sujeto en necesidad del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161480743P | 2011-04-29 | 2011-04-29 | |
PCT/US2012/035831 WO2012149546A2 (en) | 2011-04-29 | 2012-04-30 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013012346A MX2013012346A (es) | 2014-08-22 |
MX365365B true MX365365B (es) | 2019-05-30 |
Family
ID=47068061
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013012346A MX365365B (es) | 2011-04-29 | 2012-04-30 | Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer. |
MX2019006379A MX2019006379A (es) | 2011-04-29 | 2013-10-22 | Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006379A MX2019006379A (es) | 2011-04-29 | 2013-10-22 | Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. |
Country Status (16)
Country | Link |
---|---|
US (8) | US8673923B2 (es) |
EP (3) | EP2701708B1 (es) |
JP (6) | JP6132833B2 (es) |
CA (1) | CA2832342C (es) |
CY (1) | CY1123010T1 (es) |
DK (1) | DK2701708T3 (es) |
ES (1) | ES2786033T3 (es) |
HR (1) | HRP20200636T1 (es) |
HU (1) | HUE049207T2 (es) |
LT (1) | LT2701708T (es) |
MX (2) | MX365365B (es) |
PL (1) | PL2701708T3 (es) |
PT (1) | PT2701708T (es) |
RS (1) | RS60186B1 (es) |
SI (1) | SI2701708T1 (es) |
WO (1) | WO2012149546A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2701708T1 (sl) | 2011-04-29 | 2020-07-31 | The Penn State Research Foundation | Induciranje malomolekulskega gena TRAIL z normalnimi in tumorskimi celicami kot terapija proti raku |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
EP3572083A1 (en) | 2013-03-13 | 2019-11-27 | Oncoceutics, Inc. | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer |
US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
CN110669047A (zh) | 2013-11-15 | 2020-01-10 | 昂克希尔迪克斯有限公司 | 用于治疗癌症的化合物、其组合物及应用方法 |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
HUE049013T2 (hu) | 2014-03-31 | 2020-08-28 | Scripps Research Inst | Farmakofór trail indukcióra |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
HUE052821T2 (hu) * | 2015-01-30 | 2021-05-28 | Oncoceutics Inc | 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása |
US11027047B2 (en) | 2015-03-31 | 2021-06-08 | The University Of North Carolina At Chapel Hill | Delivery vehicles for stem cells and uses thereof |
CN104860948B (zh) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
EA038551B1 (ru) | 2015-12-17 | 2021-09-14 | Дзе Джонс Хопкинс Юниверсити | Способ лечения или профилактики системного склероза |
MX2018009227A (es) | 2016-01-29 | 2018-11-09 | Oncoceutics Inc | Modulacion del receptor acoplado a proteina g (gpcr) por imipridones. |
WO2017177148A1 (en) | 2016-04-07 | 2017-10-12 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA105008A (en) | 1907-02-06 | 1907-04-30 | Charles B. Grimshaw | Self-closing valve |
DE2150062A1 (de) | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
US5648097A (en) | 1995-10-04 | 1997-07-15 | Biotek, Inc. | Calcium mineral-based microparticles and method for the production thereof |
US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
EP1960552A2 (en) * | 2005-12-16 | 2008-08-27 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
ES2390237T3 (es) | 2006-02-10 | 2012-11-07 | Nerviano Medical Sciences S.R.L. | Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico |
CA2656393A1 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
WO2010009985A2 (en) * | 2008-07-24 | 2010-01-28 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
US20120183536A1 (en) * | 2009-06-24 | 2012-07-19 | Stephen Evans-Freke | Methods of using corticotropin-releasing factor for the treatment of cancer |
SI2701708T1 (sl) | 2011-04-29 | 2020-07-31 | The Penn State Research Foundation | Induciranje malomolekulskega gena TRAIL z normalnimi in tumorskimi celicami kot terapija proti raku |
EP3572083A1 (en) | 2013-03-13 | 2019-11-27 | Oncoceutics, Inc. | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer |
-
2012
- 2012-04-30 SI SI201231766T patent/SI2701708T1/sl unknown
- 2012-04-30 PL PL12776073T patent/PL2701708T3/pl unknown
- 2012-04-30 CA CA2832342A patent/CA2832342C/en active Active
- 2012-04-30 DK DK12776073.4T patent/DK2701708T3/da active
- 2012-04-30 EP EP12776073.4A patent/EP2701708B1/en active Active
- 2012-04-30 ES ES12776073T patent/ES2786033T3/es active Active
- 2012-04-30 PT PT127760734T patent/PT2701708T/pt unknown
- 2012-04-30 JP JP2014508181A patent/JP6132833B2/ja active Active
- 2012-04-30 EP EP23206770.2A patent/EP4335511A3/en active Pending
- 2012-04-30 LT LTEP12776073.4T patent/LT2701708T/lt unknown
- 2012-04-30 RS RS20200454A patent/RS60186B1/sr unknown
- 2012-04-30 MX MX2013012346A patent/MX365365B/es active IP Right Grant
- 2012-04-30 HU HUE12776073A patent/HUE049207T2/hu unknown
- 2012-04-30 EP EP20152317.2A patent/EP3679934A1/en active Pending
- 2012-04-30 US US13/459,775 patent/US8673923B2/en not_active Ceased
- 2012-04-30 WO PCT/US2012/035831 patent/WO2012149546A2/en active Application Filing
-
2013
- 2013-10-22 MX MX2019006379A patent/MX2019006379A/es unknown
-
2014
- 2014-02-27 US US14/192,329 patent/US9061032B2/en active Active
- 2014-07-22 US US14/338,055 patent/US9072744B1/en active Active
-
2015
- 2015-06-08 US US14/733,740 patent/US9452165B2/en active Active
- 2015-09-17 US US14/857,418 patent/USRE46290E1/en active Active
-
2016
- 2016-07-20 JP JP2016142086A patent/JP2016199580A/ja not_active Withdrawn
- 2016-09-19 US US15/269,114 patent/US9629842B2/en active Active
-
2017
- 2017-04-23 US US15/494,515 patent/US20170224690A1/en not_active Abandoned
-
2018
- 2018-11-08 JP JP2018210558A patent/JP2019019145A/ja not_active Withdrawn
-
2020
- 2020-04-14 CY CY20201100350T patent/CY1123010T1/el unknown
- 2020-04-21 HR HRP20200636TT patent/HRP20200636T1/hr unknown
-
2021
- 2021-09-16 JP JP2021151110A patent/JP2021185210A/ja active Pending
-
2022
- 2022-03-21 US US17/655,646 patent/US20220288079A1/en active Pending
-
2023
- 2023-03-06 JP JP2023033777A patent/JP2023060196A/ja active Pending
-
2024
- 2024-02-27 JP JP2024027432A patent/JP2024051080A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019006379A (es) | Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. | |
MX2021003858A (es) | Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
MX343706B (es) | Derivados heterocíclicos novedosos. | |
TN2014000175A1 (en) | Novel purine derivatives and their use in the treatment of disease | |
MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
MY180613A (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib | |
MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
GB201209613D0 (en) | New compounds | |
MX2015005963A (es) | Inhibidores heterociclicos de glutaminasa. | |
MY158992A (en) | Forms of rifaximin and uses thereof | |
MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
WO2012006421A3 (en) | Diagnosis and treatment of breast cancer | |
MX2014002990A (es) | Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf. | |
IN2014DN09228A (es) | ||
EP2569014A4 (en) | PROCESSING METHODS | |
MX359210B (es) | Composición de combinación de pac-1 y tamoxifeno. | |
MX336761B (es) | Compuestos para el tratamiento de cancer. | |
NZ628433A (en) | Chitosan-derived compositions | |
WO2013109055A3 (ko) | 개 유래의 자연살해세포 및 이의 대량 증식방법 | |
MX2013015347A (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
WO2013052158A3 (en) | Targeted nanovectors and their use for treatment of brain tumors | |
MX2015006096A (es) | Leucocitos como celulas de administracion para imagen y terapia de enfermedad. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |